NovoCure (NVCR) Treasury Shares (2017 - 2026)

NovoCure (NVCR) has reported Treasury Shares for 10 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.

• Quarterly Treasury Shares fell 18.56% year-over-year to $11.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $11.1 million (down 18.56% YoY) and the FY2025 annual result came in at $13.1 million, up 8.85% from the prior year.
• Treasury Shares slipped to $11.1 million in Q2 2026 per NVCR's latest filing, from $12.6 million in the prior quarter.
• Over the last five years, Treasury Shares for NVCR reached as high as $13.9 million in Q1 2025 and fell as low as $5.0 million in Q1 2022.
• A 5-year average of $9.7 million and a median of $11.6 million in 2024 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2024 — Treasury Shares soared 142.87% — and 2026, when it retreated 18.56%.
• Year by year, Treasury Shares stood at $5.4 million in 2022, then advanced by 8.1% to $5.8 million in 2023, then soared by 107.58% to $12.1 million in 2024, then grew by 8.85% to $13.1 million in 2025, then declined by 15.25% to $11.1 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $11.1 million, $12.6 million, and $13.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.